Health Outcomes Among Patients Diagnosed With Schizophrenia in the Us Veterans Health Administration Population Who Transitioned From Once-Monthly To Once-Every Paliperidone Palmitate: an Observational Retrospective Analysis
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Open Access Color
HYBRID
Green Open Access
No
OpenAIRE Downloads
OpenAIRE Views
Publicly Funded
No
BIP! Indicators
Impulse
Top 10%
Influence
Top 10%
Popularity
Top 10%
Abstract
There is limited literature on treatment patterns, healthcare resource utilization (HRU), and costs among patients who transition from once-monthly paliperidone palmitate (PP1M) to once-every-3-month paliperidone palmitate (PP3M) in a real-world setting. Hence, this study compared treatment patterns, HRU, and costs 12-month pre- and post-PP3M transition among Veteran’s Health Administration (VHA) patients with schizophrenia.
Description
Keywords
Healthcare costs, Schizophrenia, Medication adherence, Antipsychotic agents, Neurology, Paliperidone palmitate, Adult, Aged, 80 and over, Male, Administration, Oral, Veterans Health, Middle Aged, Patient Acceptance of Health Care, Drug Administration Schedule, United States, Patient Outcome Assessment, Young Adult, Paliperidone Palmitate, Schizophrenia, Humans, Female, Longitudinal Studies, Aged, Antipsychotic Agents, Retrospective Studies, Veterans
Fields of Science
03 medical and health sciences, 0302 clinical medicine
Citation
Patel, C., El, K. A., Huang, A., Wang, L., Baser, O., & Joshi, K. (August 08, 2019). Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy. 1-13.
WoS Q
Scopus Q
OpenCitations Citation Count
6
Source
Volume
36
Issue
10
Start Page
1
End Page
13
PlumX Metrics
Citations
CrossRef : 1
Scopus : 6
PubMed : 4
Captures
Mendeley Readers : 43
Google Scholar™
